Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification

被引:0
|
作者
Song, Byeong Geun [1 ]
Kim, Aryoung [1 ]
Goh, Myung Ji [1 ]
Kang, Wonseok [1 ]
Gwak, Geum-Youn [1 ]
Paik, Yong-Han [1 ]
Choi, Moon Seok [1 ]
Lee, Joon Hyeok [1 ]
Sinn, Dong Hyun [1 ]
机构
[1] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Sch Med, Seoul, South Korea
关键词
Steatotic liver disease; Metabolic dysfunction-associated steatotic liver disease; Nonalcoholic fatty liver disease; Metabolic dysfunction-associated fatty liver disease; Hepatocellular carcinoma; CONSENSUS STATEMENT; METABOLIC SYNDROME; CANCER; NAFLD; MORTALITY; FIBROSIS; ALCOHOL; OBESITY; HCC;
D O I
10.1159/000538301
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Steatotic liver disease (SLD) is a new overarching term proposed to replace nonalcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease. Subclassification includes metabolic dysfunction-associated SLD (MASLD), MASLD with increased alcohol intake (MetALD), and cryptogenic SLD. This study aimed to investigate whether SLD and its subclassification could stratify hepatocellular carcinoma (HCC) risk. Methods: A cohort of 85,119 adults without viral hepatitis or heavy alcohol intake was analyzed for the risk of HCC according to SLD and its subclassification. The fibrosis-4 (FIB-4) index was used to estimate the degree of liver fibrosis. Results: During a median follow-up of 11.9 years, HCC was diagnosed in 123 individuals. The incidence rate of HCC per 1,000 person-years was higher in individuals with SLD than in those without SLD (0.197 vs. 0.071, p < 0.001), with an adjusted hazard ratio of 2.02 (95% confidence interval: 1.40-2.92). The HCC incidence rate per 1,000 person-years was 0, 0.180, and 0.648 for cryptogenic SLD, MASLD, and MetALD, respectively. When participants with SLD was further stratified by the FIB-4 index, the HCC incidence rate per 1,000 person-years was 0.074 for SLD with FIB-4 < 1.3 and 0.673 for SLD with FIB-4 >= 1.3. Of note, HCC risk was substantially high (HCC incidence rate: 1.847 per 1,000 person-years) for MetALD with FIB-4 >= 1.3. Conclusions: HCC risk was different by SLD and its subclassification. The utilization of SLD and its subclassification can aid in stratifying HCC risk and facilitate the identification of individuals requiring interventions to mitigate the risk of HCC.<br /> (c) 2024 The Author(s).Published by S. Karger AG, Basel
引用
收藏
页码:561 / 571
页数:11
相关论文
共 50 条
  • [41] Incidence rates of hepatocellular carcinoma based on risk stratification in steatotic liver disease for precision medicine: A real-world longitudinal nationwide study
    Lai, Rongtao
    Barnett, Scott
    Zhang, Xinrong
    Kam, Leslie Yeeman
    Cheung, Ramsey
    Xie, Qing
    Nguyen, Mindie H.
    PLOS MEDICINE, 2024, 21 (10)
  • [42] An updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-Associated Steatotic Liver Disease: Trends, pathophysiology and risk-based surveillance
    Armandi, Angelo
    Rosso, Chiara
    Caviglia, Gian Paolo
    Bugianesi, Elisabetta
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2025, 162
  • [43] Human leukocyte antigen-G in hepatocellular carcinoma driven by chronic viral hepatitis or steatotic liver disease
    Stefano Mocci
    Andrea Perra
    Roberto Littera
    Francesco Pes
    Maurizio Melis
    Celeste Sanna
    Alessia Mascia
    Michela Murgia
    Caterina Mereu
    Michela Lorrai
    Irena Duś-Ilnicka
    Giorgia Zedda
    Sara Lai
    Erika Giuressi
    Federico Guarino
    Gianfranco Serra
    Michela Miglianti
    Roberta Stradoni
    Monica Vacca
    Teresa Zolfino
    Luchino Chessa
    Sabrina Giglio
    Scientific Reports, 15 (1)
  • [44] New nomenclature and subclassification of steatotic liver disease and loss of skeletal muscle mass: A longitudinal cohort study
    Kim, Aryoung
    Kang, Danbee
    Choi, Sung Chul
    Sinn, Dong Hyun
    Gwak, Geum-Youn
    HEPATOLOGY RESEARCH, 2025, 55 (03) : 373 - 383
  • [45] Lower hepatocellular carcinoma surveillance in metabolic dysfunction-associated steatotic liver disease: Impact on treatment eligibility
    Henry-Blake, Connor
    Balachandrakumar, Vinay
    Kassab, Mohamed
    Devonport, Joshua
    Matthews, Charmaine
    Fox, James
    Baggus, Elisabeth
    Henney, Alexander
    Stern, Nicholas
    Cuthbertson, Daniel J.
    Palmer, Daniel
    Johnson, Philip J.
    Hughes, David M.
    Hydes, Theresa J.
    Cross, Timothy J. S.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024,
  • [46] Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma
    Salazar, Melchor Alpizar
    Reyes, Samantha Estefania Olguin
    Estevez, Andrea Medina
    Lobos, Julieta Alejandra Saturno
    Castillo, Jesus Manuel De Aldecoa
    Aguas, Juan Carlos Carrera
    Monreal, Samary Alaniz
    Rodriguez, Jose Antonio Navarro
    Sanchez, Dulce Maria Fernanda Alpizar
    MEDICINA-LITHUANIA, 2025, 61 (01):
  • [47] Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease
    Donadon, Valter
    Balbi, Massimiliano
    Ghersetti, Michela
    Grazioli, Silvia
    Perciaccante, Antonio
    Della Valentina, Giovanni
    Gardenal, Rita
    Dal Mas, Maria
    Casarin, Pietro
    Zanette, Giorgio
    Miranda, Cesare
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (20) : 2506 - 2511
  • [48] Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease
    Valter Donadon
    Massimiliano Balbi
    Michela Ghersetti
    Silvia Grazioli
    Antonio Perciaccante
    Giovanni Della Valentina
    Rita Gardenal
    Maria Dal Mas
    Pietro Casarin
    Giorgio Zanette
    Cesare Miranda
    World Journal of Gastroenterology, 2009, 15 (20) : 2506 - 2511
  • [49] Genetic risk markers for hepatocellular carcinoma in patients with alcoholic liver disease
    Nahon, Pierre
    Sutton, Angela
    Ziol, Marianne
    Zucman-Rossi, Jessica
    Trinchet, Jean-Claude
    Ganne-Carrie, Nathalie
    HEPATIC ONCOLOGY, 2015, 2 (01) : 63 - 78
  • [50] HEPATOCELLULAR CARCINOMA RISK SCORES FOR NONVIRAL LIVER DISEASE: A SYSTEMATIC REVIEW
    Burke, Laura
    Hinkson, Alex
    Jones, Rebecca
    Parker, Richard
    Rowe, Ian
    GUT, 2023, 72 : A45 - A45